Τα Solta Medical's Thermage(R) FLX and TR-4 Return Pad λαμβάνουν πιστοποιήσεις εγγραφής στην Κίνα

LAVAL, QC, Jan 23, 2024 – (ACN Newswire) – Bausch Health Companies Inc. (NYSE/TSX:BHC) and Solta Medical, a global leader in the medical aesthetics market, today announced the approval of Thermage® FLX and the TR-4 Return Pad by China’s National Medical Products Administration (NMPA). [Δείτε *Διόρθωση παραπάνω: Το TR-4 Return Pad δεν έχει εγκριθεί για χρήση από τον Οργανισμό Τροφίμων και Φαρμάκων των ΗΠΑ.]

“The approval of Thermage FLX, and the TR-4 return pad, marks a significant milestone for Solta Medical,” Thomas J. Appio, Bausch Health Chief Executive Officer, said. “Not only is this important for growing our business, but it also represents an enormous achievement for our R&D and Regulatory Teams, who worked tirelessly with the NMPA.”

Thermage is a non-invasive treatment that uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin’s surface to optimize a patient’s appearance. Thermage is a versatile and effective treatment that can be used on all skin types and genders, on a wide range of areas on the face, body and around the eyes. Globally, more than two million Thermage treatments have been performed.

“The approval from NMPA means we are able to continue the momentum of the growth of Thermage in China,” Jiny Kim, Senior Vice President, Solta Medical, said. “Building on the legacy of Thermage CPT, which has been serving Chinese institutions and consumers effectively since 2015, we look forward to delivering the Thermage FLX proven technology to the Chinese market.”

Ενδείξεις

• Τα εξαρτήματα παροχής ενέργειας μόνο από ραδιοσυχνότητες του συστήματος Thermage® CPT και FLX και των αξεσουάρ ενδείκνυνται για χρήση σε:

o Μη επεμβατική θεραπεία των ρυτίδων γύρω από τα μάτια, συμπεριλαμβανομένων των άνω και κάτω βλεφάρων

o Μη επεμβατική αντιμετώπιση των ρυτίδων

• Η ταυτόχρονη εφαρμογή ενέργειας ραδιοσυχνοτήτων και δόνησης δέρματος από το σύστημα Thermage® CPT και FLX και τα αξεσουάρ ενδείκνυται για χρήση σε:

o Μη επεμβατική θεραπεία των ρυτίδων γύρω από το μάτι

o Μη επεμβατική αντιμετώπιση των ρυτίδων

o Προσωρινή βελτίωση στην εμφάνιση της κυτταρίτιδας

Σημαντικές πληροφορίες για την ασφάλεια

Μην υποβληθείτε σε θεραπεία Thermage εάν έχετε καρδιακό βηματοδότη, καρδιομετατροπέα, απινιδωτή ή οποιοδήποτε άλλο ηλεκτρικό εμφύτευμα. Ενημερώστε το γιατρό σας εάν έχετε ηλεκτρικό εμφύτευμα ή εάν έχετε οποιεσδήποτε ερωτήσεις σχετικά με το εάν πρέπει να υποβληθείτε σε θεραπεία Thermage®.

Η Solta Medical δεν έχει μελετήσει τη χρήση του συστήματος Thermage:

– Over skin fillers (lips, cheeks, facial wrinkles and skin folds)

– In people who are pregnant and/or breast feeding, diabetic, have an auto-immune disease such as lupus, have cold sores, have genital herpes, or have epilepsy

– In people who have permanent make-up and/or tattoos

– In children

Η πιο συχνά αναφερόμενη ανεπιθύμητη ενέργεια κατά τη διάρκεια της θεραπείας είναι ήπιος έως μέτριος πόνος στην περιοχή που αντιμετωπίζεται.

Οι πιο συχνά αναφερόμενες ανεπιθύμητες ενέργειες μετά τη θεραπεία περιλαμβάνουν τα ακόλουθα:

– Mild redness may occur and typically resolves within 24 hours.

– Swelling may occur and typically resolves within 5 days but can remain up to several weeks.

Οι ακόλουθες ανεπιθύμητες ενέργειες εμφανίζονται σπάνια:

– The procedure may produce heating in the upper layers of the skin, causing burns and subsequent blister and scab formation. There is a possibility of scar formation.

– Skin surface irregularities may appear up to 1 or more months post-treatment.

– Numbness, tingling” or temporary paralysis may occur; typically resolves in a short period of time but may persist up to several weeks.

– Lumps or nodules may occur under the skin primarily in the neck area, and usually resolve within 1 or 2 weeks without chronic or long-term complications.

– Skin may darken, but normally resolves within several months.

Ρωτήστε το γιατρό σας για περισσότερες πληροφορίες σχετικά με το Thermage FLX και δείτε www.thermage.com για περισσότερες λεπτομέρειες.

Σχετικά με τη Solta Medical

Solta Medical, a business unit of Bausch Health, is a global leader in the medical aesthetics market. Our vision at Solta is to develop and support trusted aesthetic brands that provide value to our customers and their patients. The Thermage® RF systems, Fraxel® laser, Clear + Brilliant® laser, and VASER® ultrasonic system provide exceptional results for patients and lasting growth to physicians due to our foundation of brands that have stood the test of time. More than five million procedures have been performed with Solta Medical’s portfolio of products around the world. More information can be found at www.solta.com.

Σχετικά με το Bausch Health

Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people’s lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our controlling ownership interest in Bausch +Lomb. With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

Προσωρινές δηλώσεις

This news release may contain forward-looking statements about the future performance of Bausch Health, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions, including statements about the expected results of, and market for, the Company’s Thermage® treatment. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health’s overall business, including those more fully described in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.

Θέμα: Σύνοψη δελτίου τύπου

πηγή: Bausch Health Companies Inc.
Τομείς: BioTech, Υγειονομική περίθαλψη & Pharm

https://www.acnnewswire.com

Από το δίκτυο εταιρικών ειδήσεων της Ασίας

Πνευματικά δικαιώματα © 2024 ACN Newswire. Ολα τα δικαιώματα διατηρούνται. Ένα τμήμα του δικτύου εταιρικών ειδήσεων της Ασίας.

• SEO Powered Content & PR Distribution. Ενισχύστε σήμερα.
• PlatoData.Network Vertical Generative Ai. Ενδυναμώστε τον εαυτό σας. Πρόσβαση εδώ.
• PlatoAiStream. Web3 Intelligence. Ενισχύθηκε η γνώση. Πρόσβαση εδώ.
• PlatoESG. Ανθρακας, Cleantech, Ενέργεια, Περιβάλλον, Ηλιακός, Διαχείριση των αποβλήτων. Πρόσβαση εδώ.
• PlatoHealth. Ευφυΐα βιοτεχνολογίας και κλινικών δοκιμών. Πρόσβαση εδώ.
• πηγή: https://www.acnnewswire.com/press-release/english/88669/